0.221 -0.035 (-13.65%) | 03-18 10:17 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 13.12 | 1-year : | 15.33 |
Resists | First : | 11.23 | Second : | 13.12 |
Pivot price | 11.09 | |||
Supports | First : | 11.03 | Second : | 10.9 |
MAs | MA(5) : | 11.15 | MA(20) : | 11.08 |
MA(100) : | 10.75 | MA(250) : | 10.6 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 72.7 | D(3) : | 70.7 |
RSI | RSI(14): 56.3 | |||
52-week | High : | 11.3 | Low : | 9.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MUC ] has closed below upper band by 25.7%. Bollinger Bands are 35.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 11.23 - 11.27 | 11.27 - 11.32 |
Low: | 11.03 - 11.08 | 11.08 - 11.13 |
Close: | 11.1 - 11.18 | 11.18 - 11.25 |
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
Sat, 16 Mar 2024
Head to Head Contrast: Novartis (NYSE:NVS) vs. EOM Pharmaceuticals (OTCMKTS:IMUC) - Defense World
Thu, 07 Mar 2024
EOM Pharmaceuticals (OTCMKTS:IMUC) Trading 14.3% Higher - American Banking and Market News - American Banking News
Thu, 07 Mar 2024
EOM Pharmaceuticals (OTCMKTS:IMUC) Stock Price Up 14.3% - Defense World
Thu, 10 Nov 2022
EOM PHARMACEUTICAL HOLDINGS, INC. ANNOUNCES NAME CHANGE FROM IMMUNOCELLULAR ... - BioSpace
Thu, 02 Dec 2021
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger ... - PR Newswire
Tue, 11 Apr 2017
For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1 - TheStreet
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
PNK
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 95 (M) |
Shares Float | 0 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 31.7 (%) |
Shares Short | 137 (K) |
Shares Short P.Month | 191 (K) |
EPS | -0.26 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 12.68 |
Profit Margin | -39.2 % |
Operating Margin | 86.5 % |
Return on Assets (ttm) | 2 % |
Return on Equity (ttm) | -2.4 % |
Qtrly Rev. Growth | 21.3 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.79 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 327 (M) |
Levered Free Cash Flow | 24 (M) |
PE Ratio | -43.01 |
PEG Ratio | 0 |
Price to Book value | 0.88 |
Price to Sales | 13.97 |
Price to Cash Flow | 3.26 |
Dividend | 0.05 |
Forward Dividend | 0 |
Dividend Yield | 0.4% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |